CA2413883A1 - Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation - Google Patents

Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation Download PDF

Info

Publication number
CA2413883A1
CA2413883A1 CA002413883A CA2413883A CA2413883A1 CA 2413883 A1 CA2413883 A1 CA 2413883A1 CA 002413883 A CA002413883 A CA 002413883A CA 2413883 A CA2413883 A CA 2413883A CA 2413883 A1 CA2413883 A1 CA 2413883A1
Authority
CA
Canada
Prior art keywords
versus
host
graft
tissue damage
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002413883A
Other languages
French (fr)
Other versions
CA2413883C (en
Inventor
George B. Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enteron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2413883A1 publication Critical patent/CA2413883A1/en
Application granted granted Critical
Publication of CA2413883C publication Critical patent/CA2413883C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for preventing tissue damage associated with graft-versus-host disease in a patient having undergone hematopoietic cell transplantation, and host-versus-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a prophylactically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate, for a period of time following hematopoietic cell or organ allograft transplantation, and prior to the presentation of symptoms associated with graft-versus-host disease or host-versus-graft disease. Representative tissues includes tissue of the intestine and liver, while representative tissue damage includes inflammation thereof.
CA002413883A 2000-05-22 2000-05-22 Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation Expired - Lifetime CA2413883C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/014064 WO2001089529A1 (en) 2000-05-22 2000-05-22 Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

Publications (2)

Publication Number Publication Date
CA2413883A1 true CA2413883A1 (en) 2001-11-29
CA2413883C CA2413883C (en) 2009-07-28

Family

ID=21741408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002413883A Expired - Lifetime CA2413883C (en) 2000-05-22 2000-05-22 Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

Country Status (3)

Country Link
AU (1) AU2000250389A1 (en)
CA (1) CA2413883C (en)
WO (1) WO2001089529A1 (en)

Also Published As

Publication number Publication date
CA2413883C (en) 2009-07-28
AU2000250389A1 (en) 2001-12-03
WO2001089529A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
Mourelle et al. Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase
US20030224071A1 (en) Pharmaceutical compositions and methods for managing connective tissue ailments
US6676977B2 (en) Pharmaceutical compositions and methods for reducing the appearance of cellulite
WO2007032962A3 (en) Compositions and methods for intranasal delivery of tricyclic cannabinoids
US6964952B2 (en) Therapeutic composition for broad spectrum dermal disease
AU609090B2 (en) Composition for treatment of acne
CA2389167A1 (en) Pharmaceutical formulations of resveratrol and methods of use thereof
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
CA2477301A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
AR021922A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS, BUDESONIDO AND FORMOTEROL.
CA2373852A1 (en) Oligosaccharide aldonic acids and their topical use
EP2450433A3 (en) Methods of preparing and using stem cell compositions and kits comprising the same
Swanson Prevention of dry socket: an overview
US20050281820A1 (en) Compositions and methods for treating burns
EP1057484A4 (en) Cell death inhibitors
CA2271162A1 (en) Stearidonic acid compositions and uses thereof
AR021921A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS AND BUDESONIDO.
NO20055601L (en) Pharmaceutical preparation in the form of a hydrogel for transdermal administration of active ingredients
Misseghers et al. Clinical observations of the treatment of canine perianal fistulas with topical tacrolimus in 10 dogs.
WO2001074807A1 (en) Indolylpyrrole derivatives and cell death inhibitors
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
JP2000143486A (en) Skin preparation for external use
WO2006041939A3 (en) Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
EP1152002A4 (en) Pyrrole derivatives and cell death inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200522